{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:31:10Z","timestamp":1791192670758,"version":"4.1.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/nrd3459","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T09:38:17Z","timestamp":1312191497000},"page":"621-637","source":"Crossref","is-referenced-by-count":141,"title":["Targeting RNA to treat neuromuscular disease"],"prefix":"10.1038","volume":"10","author":[{"given":"Francesco","family":"Muntoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,1]]},"reference":[{"key":"BFnrd3459_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nrm2024","volume":"7","author":"KE Davies","year":"2006","unstructured":"Davies, K. E. & Nowak, K. J. Molecular mechanisms of muscular dystrophies: old and new players. Nature Rev. Mol. Cell Biol. 7, 762\u2013773 (2006).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrd3459_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9, 177\u2013189 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrd3459_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77\u201393 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrd3459_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731\u2013740 (2003).","journal-title":"Lancet Neurol."},{"key":"BFnrd3459_CR5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/adc.2007.118141","volume":"93","author":"AY Manzur","year":"2008","unstructured":"Manzur, A. Y., Kinali, M. & Muntoni, F. Update on the management of Duchenne muscular dystrophy. Arch. Dis. Child. 93, 986\u2013990 (2008).","journal-title":"Arch. Dis. Child."},{"key":"BFnrd3459_CR6","volume-title":"Duchenne Muscular Dystrophy","author":"A Emery","year":"2003","unstructured":"Emery, A. & Muntoni, F. (eds) Duchenne Muscular Dystrophy (Oxford University Press, New York, 2003)."},{"key":"BFnrd3459_CR7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H., Jr & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","journal-title":"Cell"},{"key":"BFnrd3459_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/science.3659917","volume":"238","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Monaco, A. P., Feener, C. C. & Kunkel, L. M. Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 238, 347\u2013350 (1987).","journal-title":"Science"},{"issue":"Suppl. 2","key":"BFnrd3459_CR9","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1093\/hmg\/ddl181","volume":"2006","author":"RJ Osborne","year":"2006","unstructured":"Osborne, R. J. & Thornton, C. A. RNA-dominant diseases. Hum. Mol. Genet. 2006 (Suppl. 2), R162\u2013R169 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.neuro.29.051605.113014","volume":"29","author":"LP Ranum","year":"2006","unstructured":"Ranum, L. P. & Cooper, T. A. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29, 259\u2013277 (2006).","journal-title":"Annu. Rev. Neurosci."},{"key":"BFnrd3459_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/WCO.0b013e3282ef6064","volume":"20","author":"TM Wheeler","year":"2007","unstructured":"Wheeler, T. M. & Thornton, C. A. Myotonic dystrophy: RNA-mediated muscle disease. Curr. Opin. Neurol. 20, 572\u2013576 (2007).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrd3459_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AH Burghes","year":"2009","unstructured":"Burghes, A. H. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nature Rev. Neurosci. 10, 597\u2013609 (2009).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrd3459_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-2001-15264","volume":"21","author":"K Talbot","year":"2001","unstructured":"Talbot, K. & Davies, K. E. Spinal muscular atrophy. Semin. Neurol. 21, 189\u2013197 (2001).","journal-title":"Semin. Neurol."},{"key":"BFnrd3459_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2008.03.031","volume":"133","author":"Z Zhang","year":"2008","unstructured":"Zhang, Z. et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133, 585\u2013600 (2008).","journal-title":"Cell"},{"key":"BFnrd3459_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson, M. L. & Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl Acad. Sci. USA 75, 285\u2013288 (1978).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jama.280.10.871-JMN0909-6-1","volume":"280","author":"C Marwick","year":"1998","unstructured":"Marwick, C. First \u201cantisense\u201d drug will treat CMV retinitis. JAMA 280, 871 (1998).","journal-title":"JAMA"},{"key":"BFnrd3459_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","volume":"270","author":"J Kurreck","year":"2003","unstructured":"Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628\u20131644 (2003).","journal-title":"Eur. J. Biochem."},{"key":"BFnrd3459_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.pharmtox.41.1.403","volume":"41","author":"I Lebedeva","year":"2001","unstructured":"Lebedeva, I. & Stein, C. A. Antisense oligonucleotides: promise and reality. Annu. Rev. Pharmacol. Toxicol. 41, 403\u2013419 (2001).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFnrd3459_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrd837","volume":"1","author":"JB Opalinska","year":"2002","unstructured":"Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles and recent applications. Nature Rev. Drug Discov. 1, 503\u2013514 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3459_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259\u2013293 (2010).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFnrd3459_CR21","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl Acad. Sci. USA 90, 8673\u20138677 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR22","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/hmg\/9.17.2507","volume":"9","author":"A Ahmad","year":"2000","unstructured":"Ahmad, A., Brinson, M., Hodges, B. L., Chamberlain, J. S. & Amalfitano, A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy. Hum. Mol. Genet. 9, 2507\u20132515 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR23","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1093\/hmg\/ddn162","volume":"17","author":"MM Ghahramani Seno","year":"2008","unstructured":"Ghahramani Seno, M. M. et al. RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. Hum. Mol. Genet. 17, 2622\u20132632 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/BF00858725","volume":"240","author":"KM Bushby","year":"1993","unstructured":"Bushby, K. M. & Gardner-Medwin, D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J. Neurol. 240, 98\u2013104 (1993).","journal-title":"J. Neurol."},{"key":"BFnrd3459_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrd1085","volume":"2","author":"TS Khurana","year":"2003","unstructured":"Khurana, T. S. & Davies, K. E. Pharmacological strategies for muscular dystrophy. Nature Rev. Drug Discov. 2, 379\u2013390 (2003).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3459_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature05406","volume":"444","author":"JS Chamberlain","year":"2006","unstructured":"Chamberlain, J. S. Stem-cell biology: a move in the right direction. Nature 444, 552\u2013553 (2006).","journal-title":"Nature"},{"key":"BFnrd3459_CR27","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.mt.6300161","volume":"15","author":"Z Wang","year":"2007","unstructured":"Wang, Z. et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160\u20131166 (2007).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010). This study reported the detection of dystrophin-specific T cells targeting truncated dystrophin epitopes following the delivery of a functional dystrophin transgene in patients with DMD.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3459_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/17460751.2.3.275","volume":"2","author":"SE Berry","year":"2007","unstructured":"Berry, S. E., Liu, J., Chaney, E. J. & Kaufman, S. J. Multipotential mesoangioblast stem cell therapy in the mdx\/utrn\u2212\/\u2212 mouse model for Duchenne muscular dystrophy. Regen. Med. 2, 275\u2013288 (2007).","journal-title":"Regen. Med."},{"key":"BFnrd3459_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1083\/jcb.200512085","volume":"174","author":"BG Galvez","year":"2006","unstructured":"Galvez, B. G. et al. Complete repair of dystrophic skeletal muscle by mesoangioblasts with enhanced migration ability. J. Cell Biol. 174, 231\u2013243 (2006).","journal-title":"J. Cell Biol."},{"key":"BFnrd3459_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ncb1542","volume":"9","author":"A Dellavalle","year":"2007","unstructured":"Dellavalle, A. et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biol. 9, 255\u2013267 (2007).","journal-title":"Nature Cell Biol."},{"key":"BFnrd3459_CR32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrg1180","volume":"4","author":"JC van Deutekom","year":"2003","unstructured":"van Deutekom, J. C. & van Ommen, G. J. Advances in Duchenne muscular dystrophy gene therapy. Nature Rev. Genet. 4, 774\u2013783 (2003).","journal-title":"Nature Rev. Genet."},{"key":"BFnrd3459_CR33","doi-asserted-by":"publisher","first-page":"C1090","DOI":"10.1152\/ajpcell.00450.2001","volume":"283","author":"RW Grange","year":"2002","unstructured":"Grange, R. W., Gainer, T. G., Marschner, K. M., Talmadge, R. J. & Stull, J. T. Fast-twitch skeletal muscles of dystrophic mouse pups are resistant to injury from acute mechanical stress. Am. J. Physiol. Cell Physiol. 283, C1090\u2013C1101 (2002).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"BFnrd3459_CR34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/hmg\/7.7.1083","volume":"7","author":"MG Dunckley","year":"1998","unstructured":"Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C. & Dickson, G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7, 1083\u20131090 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","volume":"226","author":"ZA Pramono","year":"1996","unstructured":"Pramono, Z. A. et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. 226, 445\u2013449 (1996).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrd3459_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI117693","volume":"95","author":"Y Takeshima","year":"1995","unstructured":"Takeshima, Y., Nishio, H., Sakamoto, H., Nakamura, H. & Matsuo, M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J. Clin. Invest. 95, 515\u2013520 (1995).","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"BFnrd3459_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0960-8966(02)00086-X","volume":"12","author":"A Aartsma-Rus","year":"2002","unstructured":"Aartsma-Rus, A. et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12 (Suppl. 1), 71\u201377 (2002).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrd3459_CR38","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.gt.3302313","volume":"11","author":"A Aartsma-Rus","year":"2004","unstructured":"Aartsma-Rus, A. et al. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 11, 1391\u20131398 (2004).","journal-title":"Gene Ther."},{"key":"BFnrd3459_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nmd.2009.10.013","volume":"20","author":"LJ Popplewell","year":"2010","unstructured":"Popplewell, L. J. et al. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials. Neuromuscul. Disord. 20, 102\u2013110 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrd3459_CR40","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mt.2008.287","volume":"17","author":"LJ Popplewell","year":"2009","unstructured":"Popplewell, L. J., Trollet, C., Dickson, G. & Graham, I. R. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol. Ther. 17, 554\u2013561 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","volume":"10","author":"JC van Deutekom","year":"2001","unstructured":"van Deutekom, J. C. et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10, 1547\u20131554 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","volume":"81","author":"G Bulfield","year":"1984","unstructured":"Bulfield, G., Siller, W. G., Wight, P. A. & Moore, K. J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA 81, 1189\u20131192 (1984).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR43","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm897","volume":"9","author":"QL Lu","year":"2003","unstructured":"Lu, Q. L. et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nature Med. 9, 1009\u20131014 (2003). This was the first in vivo study reporting the restoration of functional dystrophin protein following the intramuscular administration of an antisense oligonucleotide in the mdx mouse.","journal-title":"Nature Med."},{"key":"BFnrd3459_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1073\/pnas.98.1.42","volume":"98","author":"CJ Mann","year":"2001","unstructured":"Mann, C. J. et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl Acad. Sci. USA 98, 42\u201347 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/jgm.295","volume":"4","author":"CJ Mann","year":"2002","unstructured":"Mann, C. J., Honeyman, K., McClorey, G., Fletcher, S. & Wilton, S. D. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. 4, 644\u2013654 (2002).","journal-title":"J. Gene Med."},{"key":"BFnrd3459_CR46","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/nbt759","volume":"20","author":"P Sazani","year":"2002","unstructured":"Sazani, P. et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nature Biotech. 20, 1228\u20131233 (2002).","journal-title":"Nature Biotech."},{"key":"BFnrd3459_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu, Q. L. et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl Acad. Sci. USA 102, 198\u2013203 (2005). This was the first in vivo study reporting the successful restoration of dystrophin protein in multiple peripheral muscle groups following the systemic intravenous administration of an antisense oligonucleotide in the mdx mouse.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR48","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","volume":"18","author":"H Heemskerk","year":"2010","unstructured":"Heemskerk, H. et al. Preclinical PK and PD studies on 2\u2032-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 18, 1210\u20131217 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter, J. et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Med. 12, 175\u2013177 (2006).","journal-title":"Nature Med."},{"key":"BFnrd3459_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota, T. et al. Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann. Neurol. 65, 667\u2013676 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrd3459_CR51","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/mt.2010.261","volume":"19","author":"A Malerba","year":"2011","unstructured":"Malerba, A. et al. Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol. Ther. 19, 345\u2013354 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1089\/hum.2008.157","volume":"20","author":"A Malerba","year":"2009","unstructured":"Malerba, A., Thorogood, F. C., Dickson, G. & Graham, I. R. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum. Gene Ther. 20, 955\u2013965 (2009).","journal-title":"Hum. Gene Ther."},{"key":"BFnrd3459_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/gt.2009.120","volume":"17","author":"B Wu","year":"2010","unstructured":"Wu, B. et al. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther. 17, 132\u2013140 (2010).","journal-title":"Gene Ther."},{"key":"BFnrd3459_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10741-009-9156-8","volume":"15","author":"A Fayssoil","year":"2010","unstructured":"Fayssoil, A., Nardi, O., Orlikowski, D. & Annane, D. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail. Rev. 15, 103\u2013107 (2010).","journal-title":"Heart Fail. Rev."},{"key":"BFnrd3459_CR55","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/jgm.1288","volume":"11","author":"HA Heemskerk","year":"2009","unstructured":"Heemskerk, H. A. et al. In vivo comparison of 2\u2032-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257\u2013266 (2009).","journal-title":"J. Gene Med."},{"key":"BFnrd3459_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0167-4781(99)00140-2","volume":"1489","author":"AA Levin","year":"1999","unstructured":"Levin, A. A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69\u201384 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrd3459_CR57","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","volume":"2","author":"SP Henry","year":"2002","unstructured":"Henry, S. P. et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol. 2, 1657\u20131666 (2002).","journal-title":"Int. Immunopharmacol."},{"key":"BFnrd3459_CR58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/jgm.1446","volume":"12","author":"Q Wang","year":"2010","unstructured":"Wang, Q. et al. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J. Gene Med. 12, 354\u2013364 (2010).","journal-title":"J. Gene Med."},{"key":"BFnrd3459_CR59","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/hmg\/ddq477","volume":"20","author":"A Crisp","year":"2011","unstructured":"Crisp, A. et al. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum. Mol. Genet. 20, 413\u2013421 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR60","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJM199309233291304","volume":"329","author":"F Muntoni","year":"1993","unstructured":"Muntoni, F. et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N. Engl. J. Med. 329, 921\u2013925 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3459_CR61","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/mt.2008.52","volume":"16","author":"D Townsend","year":"2008","unstructured":"Townsend, D., Yasuda, S., Li, S., Chamberlain, J. S. & Metzger, J. M. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol. Ther. 16, 832\u2013835 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR62","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/sj.gt.3302800","volume":"13","author":"G McClorey","year":"2006","unstructured":"McClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S. & Wilton, S. D. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13, 1373\u20131381 (2006).","journal-title":"Gene Ther."},{"key":"BFnrd3459_CR63","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1021\/bc0501045","volume":"16","author":"MH Nelson","year":"2005","unstructured":"Nelson, M. H. et al. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug. Chem. 16, 959\u2013966 (2005).","journal-title":"Bioconjug. Chem."},{"key":"BFnrd3459_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1042\/BST0350053","volume":"35","author":"S Abes","year":"2007","unstructured":"Abes, S. et al. Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem. Soc. Trans. 35, 53\u201355 (2007).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrd3459_CR65","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jconrel.2006.09.011","volume":"116","author":"S Abes","year":"2006","unstructured":"Abes, S. et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control Release 116, 304\u2013313 (2006).","journal-title":"J. Control Release"},{"key":"BFnrd3459_CR66","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","volume":"18","author":"A Amantana","year":"2007","unstructured":"Amantana, A. et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18, 1325\u20131331 (2007).","journal-title":"Bioconjug. Chem."},{"key":"BFnrd3459_CR67","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/sj.mt.6300245","volume":"15","author":"S Fletcher","year":"2007","unstructured":"Fletcher, S. et al. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 15, 1587\u20131592 (2007).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR68","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2008.120","volume":"16","author":"N Jearawiriyapaisarn","year":"2008","unstructured":"Jearawiriyapaisarn, N. et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624\u20131629 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR69","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.1073\/pnas.0805676105","volume":"105","author":"B Wu","year":"2008","unstructured":"Wu, B. et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc. Natl Acad. Sci. USA 105, 14814\u201314819 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.mt.6300329","volume":"16","author":"H Yin","year":"2008","unstructured":"Yin, H., Lu, Q. & Wood, M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16, 38\u201345 (2008). The studies in Refs 68\u201370 reported a considerably enhanced restoration of dystrophin protein following the systemic administration of a peptide-conjugated antisense oligonucleotide.","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR71","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1042\/BST0350826","volume":"35","author":"HM Moulton","year":"2007","unstructured":"Moulton, H. M. et al. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem. Soc. Trans. 35, 826\u2013828 (2007).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrd3459_CR72","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.04976.x","volume":"1175","author":"HM Moulton","year":"2009","unstructured":"Moulton, H. M. et al. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Ann. NY Acad. Sci. 1175, 55\u201360 (2009).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrd3459_CR73","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/(SICI)1097-4598(199904)22:4<460::AID-MUS6>3.0.CO;2-L","volume":"22","author":"TI Samoylova","year":"1999","unstructured":"Samoylova, T. I. & Smith, B. F. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve 22, 460\u2013466 (1999).","journal-title":"Muscle Nerve"},{"key":"BFnrd3459_CR74","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-1-60761-919-2_23","volume":"683","author":"H Yin","year":"2011","unstructured":"Yin, H., Moulton, H., Betts, C. & Wood, M. CPP-directed oligonucleotide exon skipping in animal models of Duchenne muscular dystrophy. Methods Mol. Biol. 683, 321\u2013338 (2011).","journal-title":"Methods Mol. Biol."},{"key":"BFnrd3459_CR75","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/mt.2010.151","volume":"18","author":"H Yin","year":"2010","unstructured":"Yin, H. et al. Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol. Ther. 18, 1822\u20131829 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR76","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1093\/hmg\/ddp395","volume":"18","author":"H Yin","year":"2009","unstructured":"Yin, H. et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum. Mol. Genet. 18, 4405\u20134414 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR77","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/mt.2011.79","volume":"19","author":"H Yin","year":"2011","unstructured":"Yin, H. et al. Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19, 1295\u20131303 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR78","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1093\/nar\/gkn671","volume":"36","author":"GD Ivanova","year":"2008","unstructured":"Ivanova, G. D. et al. Improved cell-penetrating peptide\u2013PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 36, 6418\u20136428 (2008).","journal-title":"Nucleic Acids Res."},{"key":"BFnrd3459_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/nass\/nrn016","volume":"52","author":"GD Ivanova","year":"2008","unstructured":"Ivanova, G. D. et al. PNA-peptide conjugates as intracellular gene control agents. Nucleic Acids Symp. Ser. (Oxf.) 52, 31\u201332 (2008).","journal-title":"Nucleic Acids Symp. Ser. (Oxf.)"},{"key":"BFnrd3459_CR80","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","volume":"5","author":"A Amantana","year":"2005","unstructured":"Amantana, A. & Iversen, P. L. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 5, 550\u2013555 (2005).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrd3459_CR81","first-page":"235","volume":"3","author":"PL Iversen","year":"2001","unstructured":"Iversen, P. L. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3, 235\u2013238 (2001).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"BFnrd3459_CR82","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0022-3565(25)12951-0","volume":"277","author":"ST Crooke","year":"1996","unstructured":"Crooke, S. T. et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923\u2013937 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3459_CR83","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0022-510X(95)00147-T","volume":"132","author":"L Morandi","year":"1995","unstructured":"Morandi, L. et al. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype. J. Neurol. Sci. 132, 146\u2013155 (1995).","journal-title":"J. Neurol. Sci."},{"key":"BFnrd3459_CR84","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918\u2013928 (2009).","journal-title":"Lancet Neurol."},{"key":"BFnrd3459_CR85","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1056\/NEJMoa073108","volume":"357","author":"JC van Deutekom","year":"2007","unstructured":"van Deutekom, J. C. et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677\u20132686 (2007). This was the first clinical study to report the successful restoration of dystrophin protein following the intramuscular administration of a 2OMe antisense oligonucleotide in patients with DMD.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3459_CR86","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4161\/rna.7.4.12264","volume":"7","author":"A Aartsma-Rus","year":"2010","unstructured":"Aartsma-Rus, A. Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol. 7, 453\u2013461 (2010).","journal-title":"RNA Biol."},{"key":"BFnrd3459_CR87","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus, A. et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293\u2013299 (2009).","journal-title":"Hum. Mutat."},{"key":"BFnrd3459_CR88","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nmd.2010.01.013","volume":"20","author":"AT Helderman-van den Enden","year":"2010","unstructured":"Helderman-van den Enden, A. T. et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul. Disord. 20, 251\u2013254 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrd3459_CR89","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.gt.3301955","volume":"10","author":"D Furling","year":"2003","unstructured":"Furling, D. et al. Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene Ther. 10, 795\u2013802 (2003).","journal-title":"Gene Ther."},{"key":"BFnrd3459_CR90","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pediatrneurol.2006.01.004","volume":"35","author":"M Saengpattrachai","year":"2006","unstructured":"Saengpattrachai, M., Ray, P. N., Hawkins, C. E., Berzen, A. & Banwell, B. L. Grandpa and I have dystrophinopathy?: approach to asymptomatic hyperCKemia. Pediatr. Neurol. 35, 145\u2013149 (2006).","journal-title":"Pediatr. Neurol."},{"key":"BFnrd3459_CR91","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans, N. M. et al. Systemic administration of PRO051 in duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513\u20131522 (2011). This was another clinical study that reported the successful restoration of dystrophin protein following systemic administration of a 2OMe antisense oligonucleotide in patients with DMD.","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3459_CR92","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.1023","volume":"49","author":"KR Wagner","year":"2001","unstructured":"Wagner, K. R. et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706\u2013711 (2001).","journal-title":"Ann. Neurol."},{"key":"BFnrd3459_CR93","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/mus.10341","volume":"27","author":"P Dunant","year":"2003","unstructured":"Dunant, P., Walter, M. C., Karpati, G. & Lochmuller, H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27, 624\u2013627 (2003).","journal-title":"Muscle Nerve"},{"key":"BFnrd3459_CR94","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1172\/JCI7866","volume":"104","author":"ER Barton-Davis","year":"1999","unstructured":"Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E. & Sweeney, H. L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104, 375\u2013381 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3459_CR95","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","volume":"67","author":"V Malik","year":"2010","unstructured":"Malik, V. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 67, 771\u2013780 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrd3459_CR96","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch, E. M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87\u201391 (2007). This study identified a chemical entity, PTC124, that selectively induced ribosomal readthrough of premature termination codons and demonstrated efficacy in promoting dystrophin protein production in primary human muscle cells and in mdx mice.","journal-title":"Nature"},{"key":"BFnrd3459_CR97","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ana.20052","volume":"55","author":"MT Howard","year":"2004","unstructured":"Howard, M. T. et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann. Neurol. 55, 422\u2013426 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrd3459_CR98","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1212\/01.WNL.0000054481.84978.F9","volume":"60","author":"JW Day","year":"2003","unstructured":"Day, J. W. et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60, 657\u2013664 (2003).","journal-title":"Neurology"},{"key":"BFnrd3459_CR99","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","volume":"13","author":"H Jiang","year":"2004","unstructured":"Jiang, H., Mankodi, A., Swanson, M. S., Moxley, R. T. & Thornton, C. A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079\u20133088 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR100","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST0371281","volume":"37","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Cooper, T. A. Pathogenic mechanisms of myotonic dystrophy. Biochem. Soc. Trans. 37, 1281\u20131286 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrd3459_CR101","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/ng1857","volume":"38","author":"MS Mahadevan","year":"2006","unstructured":"Mahadevan, M. S. et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nature Genet. 38, 1066\u20131070 (2006).","journal-title":"Nature Genet."},{"key":"BFnrd3459_CR102","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1086\/383590","volume":"74","author":"LP Ranum","year":"2004","unstructured":"Ranum, L. P. & Day, J. W. Myotonic dystrophy: RNA pathogenesis comes into focus. Am. J. Hum. Genet. 74, 793\u2013804 (2004).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrd3459_CR103","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1073\/pnas.0708519105","volume":"105","author":"JP Orengo","year":"2008","unstructured":"Orengo, J. P. et al. Expanded CTG repeats within the DMPK 3\u2032 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc. Natl Acad. Sci. USA 105, 2646\u20132651 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR104","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1093\/hmg\/ddq277","volume":"19","author":"AJ Ward","year":"2010","unstructured":"Ward, A. J., Rimer, M., Killian, J. M., Dowling, J. J. & Cooper, T. A. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum. Mol. Genet. 19, 3614\u20133622 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR105","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/ng.2007.28","volume":"40","author":"RS Yadava","year":"2008","unstructured":"Yadava, R. S. et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nature Genet. 40, 61\u201368 (2008).","journal-title":"Nature Genet."},{"key":"BFnrd3459_CR106","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1093\/nar\/gkm601","volume":"35","author":"Y Yuan","year":"2007","unstructured":"Yuan, Y. et al. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 35, 5474\u20135486 (2007).","journal-title":"Nucleic Acids Res."},{"key":"BFnrd3459_CR107","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1086\/378720","volume":"73","author":"CL Liquori","year":"2003","unstructured":"Liquori, C. L. et al. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am. J. Hum. Genet. 73, 849\u2013862 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrd3459_CR108","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/hmg\/ddl103","volume":"15","author":"JM Margolis","year":"2006","unstructured":"Margolis, J. M., Schoser, B. G., Moseley, M. L., Day, J. W. & Ranum, L. P. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum. Mol. Genet. 15, 1808\u20131815 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR109","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1126\/science.1177452","volume":"325","author":"TA Cooper","year":"2009","unstructured":"Cooper, T. A. Molecular biology. Neutralizing toxic RNA. Science 325, 272\u2013273 (2009).","journal-title":"Science"},{"key":"BFnrd3459_CR110","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/hmg\/ddp570","volume":"19","author":"M Koshelev","year":"2010","unstructured":"Koshelev, M., Sarma, S., Price, R. E., Wehrens, X. H. & Cooper, T. A. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum. Mol. Genet. 19, 1066\u20131075 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR111","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ana.22278","volume":"69","author":"JP Orengo","year":"2010","unstructured":"Orengo, J. P., Ward, A. J. & Cooper, T. A. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann. Neurol. 69, 681\u2013690 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrd3459_CR112","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1242\/jcs.02404","volume":"118","author":"TH Ho","year":"2005","unstructured":"Ho, T. H. et al. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J. Cell Sci. 118, 2923\u20132933 (2005).","journal-title":"J. Cell Sci."},{"key":"BFnrd3459_CR113","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","volume":"15","author":"X Lin","year":"2006","unstructured":"Lin, X. et al. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15, 2087\u20132097 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR114","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","volume":"28","author":"NM Kuyumcu-Martinez","year":"2007","unstructured":"Kuyumcu-Martinez, N. M., Wang, G. S. & Cooper, T. A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell 28, 68\u201378 (2007).","journal-title":"Mol. Cell"},{"key":"BFnrd3459_CR115","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1172\/JCI32308","volume":"117","author":"GS Wang","year":"2007","unstructured":"Wang, G. S., Kearney, D. L., De Biasi, M., Taffet, G. & Cooper, T. A. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J. Clin. Invest. 117, 2802\u20132811 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3459_CR116","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/hmg\/ddp058","volume":"18","author":"RJ Osborne","year":"2009","unstructured":"Osborne, R. J. et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum. Mol. Genet. 18, 1471\u20131481 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR117","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1172\/JCI37976","volume":"119","author":"GS Wang","year":"2009","unstructured":"Wang, G. S. et al. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J. Clin. Invest. 119, 3797\u20133806 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3459_CR118","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tig.2004.08.004","volume":"20","author":"LP Ranum","year":"2004","unstructured":"Ranum, L. P. & Day, J. W. Pathogenic RNA repeats: an expanding role in genetic disease. Trends Genet. 20, 506\u2013512 (2004).","journal-title":"Trends Genet."},{"key":"BFnrd3459_CR119","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nsmb.1720","volume":"17","author":"H Du","year":"2010","unstructured":"Du, H. et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nature Struct. Mol. Biol. 17, 187\u2013193 (2010).","journal-title":"Nature Struct. Mol. Biol."},{"key":"BFnrd3459_CR120","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/hmg\/ddi162","volume":"14","author":"TH Ho","year":"2005","unstructured":"Ho, T. H., Bundman, D., Armstrong, D. L. & Cooper, T. A. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum. Mol. Genet. 14, 1539\u20131547 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR121","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1093\/hmg\/ddq161","volume":"19","author":"SA Mulders","year":"2010","unstructured":"Mulders, S. A., van Engelen, B. G., Wieringa, B. & Wansink, D. G. Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. Hum. Mol. Genet. 19, R90\u2013R97 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR122","doi-asserted-by":"publisher","first-page":"18433","DOI":"10.1073\/pnas.0910643106","volume":"106","author":"TA Cooper","year":"2009","unstructured":"Cooper, T. A. Chemical reversal of the RNA gain of function in myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 18433\u201318434 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR123","doi-asserted-by":"publisher","first-page":"18551","DOI":"10.1073\/pnas.0903234106","volume":"106","author":"MB Warf","year":"2009","unstructured":"Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A. & Berglund, J. A. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 18551\u201318556 (2009). This study identified the ability of the small molecule pentamidine to reverse missplicing of pre-mRNAs that are implicated in myotonic dystrophy.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR124","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.1173110","volume":"325","author":"TM Wheeler","year":"2009","unstructured":"Wheeler, T. M. et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325, 336\u2013339 (2009). This study showed the reversal of a transgenic myotonic dystrophy phenotype using a PMO antisense oligonucleotide, CAG25, that binds to microsatellite expanded RNA and blocks its interaction with MBNL1.","journal-title":"Science"},{"key":"BFnrd3459_CR125","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.0905780106","volume":"106","author":"SA Mulders","year":"2009","unstructured":"Mulders, S. A. et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl Acad. Sci. USA 106, 13915\u201313920 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR126","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.molcel.2007.01.031","volume":"25","author":"J Krol","year":"2007","unstructured":"Krol, J. et al. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol. Cell 25, 575\u2013586 (2007). This was a report on the use of a 2OMe (CAG) 7 antisense oligonucleotide that silences RNA expression of mutated DMPK , reduces the number of ribonuclear aggregates and normalizes aberrant pre-mRNA splicing in vivo in mouse models of DM1.","journal-title":"Mol. Cell"},{"key":"BFnrd3459_CR127","doi-asserted-by":"publisher","first-page":"16949","DOI":"10.1074\/jbc.M501591200","volume":"280","author":"MA Langlois","year":"2005","unstructured":"Langlois, M. A. et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J. Biol. Chem. 280, 16949\u201316954 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3459_CR128","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.molmed.2011.01.002","volume":"17","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. & Cheng, S. H. Prospects for the gene therapy of spinal muscular atrophy. Trends Mol. Med. 17, 259\u2013265 (2011).","journal-title":"Trends Mol. Med."},{"key":"BFnrd3459_CR129","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotech. 28, 271\u2013274 (2010).","journal-title":"Nature Biotech."},{"key":"BFnrd3459_CR130","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori, C. F. et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35ra42 (2010).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd3459_CR131","first-page":"3952","volume":"117","author":"TM Wheeler","year":"2007","unstructured":"Wheeler, T. M., Lueck, J. D., Swanson, M. S., Dirksen, R. T. & Thornton, C. A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J. Clin. Invest. 117, 3952\u20133957 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3459_CR132","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3, 72ra18 (2011). This study reported the use of methoxyethyl-modified antisense oligonucleotides that were administered directly to the CNS in mice and cynomolgus monkeys, and demonstrated successful splicing redirection of the SMN2 gene.","journal-title":"Sci. Transl. Med."},{"key":"BFnrd3459_CR133","first-page":"15","volume":"22","author":"L Politano","year":"2003","unstructured":"Politano, L. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22, 15\u201321 (2003).","journal-title":"Acta Myol."},{"key":"BFnrd3459_CR134","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymthe.2006.01.012","volume":"14","author":"T Baughan","year":"2006","unstructured":"Baughan, T. et al. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther. 14, 54\u201362 (2006).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR135","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","volume":"18","author":"TD Baughan","year":"2009","unstructured":"Baughan, T. D., Dickson, A., Osman, E. Y. & Lorson, C. L. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet. 18, 1600\u20131611 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR136","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1089\/hum.2008.067","volume":"19","author":"A Dickson","year":"2008","unstructured":"Dickson, A., Osman, E. & Lorson, C. L. A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum. Gene Ther. 19, 1307\u20131315 (2008).","journal-title":"Hum. Gene Ther."},{"key":"BFnrd3459_CR137","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1073\/pnas.0633863100","volume":"100","author":"LA Skordis","year":"2003","unstructured":"Skordis, L. A., Dunckley, M. G., Yue, B., Eperon, I. C. & Muntoni, F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl Acad. Sci. USA 100, 4114\u20134119 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3459_CR138","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634\u20131644 (2010). This was the first study to demonstrate effective in vivo CNS splicing redirection of the SMN2 gene in the CNS in a mouse model of SMA.","journal-title":"Genes Dev."},{"key":"BFnrd3459_CR139","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","volume":"5","author":"Y Hua","year":"2007","unstructured":"Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F. & Krainer, A. R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5, e73 (2007).","journal-title":"PLoS Biol."},{"key":"BFnrd3459_CR140","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F. & Krainer, A. R. Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834\u2013848 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrd3459_CR141","doi-asserted-by":"crossref","unstructured":"Owen, N. et al. Design principles for bifunctional targeted oligonucleotide enhancers of splicing. Nucleic Acids Res. 20 May 2011 (doi:10.1093\/nar\/gkr152).","DOI":"10.1093\/nar\/gkr152"},{"key":"BFnrd3459_CR142","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1101\/gad.1961710","volume":"24","author":"AH Burghes","year":"2010","unstructured":"Burghes, A. H. & McGovern, V. L. Antisense oligonucleotides and spinal muscular atrophy: skipping along. Genes Dev. 24, 1574\u20131579 (2010).","journal-title":"Genes Dev."},{"key":"BFnrd3459_CR143","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nsb887","volume":"10","author":"L Cartegni","year":"2003","unstructured":"Cartegni, L. & Krainer, A. R. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nature Struct. Biol. 10, 120\u2013125 (2003).","journal-title":"Nature Struct. Biol."},{"key":"BFnrd3459_CR144","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/sj.mt.6300222","volume":"15","author":"TH Coady","year":"2007","unstructured":"Coady, T. H., Shababi, M., Tullis, G. E. & Lorson, C. L. Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol. Ther. 15, 1471\u20131478 (2007).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR145","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4161\/rna.6.3.8723","volume":"6","author":"NN Singh","year":"2009","unstructured":"Singh, N. N., Shishimorova, M., Cao, L. C., Gangwani, L. & Singh, R. N. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy. RNA Biol. 6, 341\u2013350 (2009).","journal-title":"RNA Biol."},{"key":"BFnrd3459_CR146","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/hmg\/ddn382","volume":"18","author":"K Meyer","year":"2009","unstructured":"Meyer, K. et al. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. Genet. 18, 546\u2013555 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrd3459_CR147","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotech. 29, 341\u2013345 (2011).","journal-title":"Nature Biotech."},{"key":"BFnrd3459_CR148","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/mt.2009.49","volume":"17","author":"C Mitrpant","year":"2009","unstructured":"Mitrpant, C. et al. Rational design of antisense oligomers to induce dystrophin exon skipping. Mol. Ther. 17, 1418\u20131426 (2009).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR149","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.nmd.2010.03.005","volume":"20","author":"F Muntoni","year":"2010","unstructured":"Muntoni, F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul. Disord. 20, 355\u2013362 (2010).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrd3459_CR150","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST0371281","volume":"37","author":"JE Lee","year":"2009","unstructured":"Lee, J. E. & Cooper, T. A. Pathogenic mechanisms of myotonic dystrophy. Biochem. Soc. Trans. 37, 1281\u20131286 (2009).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrd3459_CR151","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.mt.6300329","volume":"16","author":"H Yin","year":"2008","unstructured":"Yin, H., Lu, Q. & Wood, M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16, 38\u201345 (2008).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR152","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/mt.2009.310","volume":"18","author":"H Yin","year":"2010","unstructured":"Yin, H. et al. Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol. Ther. 18, 819\u2013827 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrd3459_CR153","volume-title":"European Paediatric Neurology Society Congress, 9th EPNS Congress","author":"R Quinlivan","year":"2011","unstructured":"Quinlivan, R., Kirschner, J., Comi, G. & Bushby, K. for the Ataluren DBMD Study Group. Safety and efficacy of ataluren 10,10,20 mg\/kg TID in patients with nonsense mutation dystrophinopathy. European Paediatric Neurology Society Congress, 9th EPNS Congress [online] , (2011)."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd3459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3459","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:35Z","timestamp":1741392035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd3459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":153,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["BFnrd3459"],"URL":"https:\/\/doi.org\/10.1038\/nrd3459","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}